TLPHHIGH SIGNALFINANCIAL10-K

TLPH experienced a substantial revenue decline while dramatically increasing its share count, suggesting significant dilution alongside operational challenges.

The company's outstanding shares increased from 17.1 million to 50.0 million, indicating substantial dilution that likely funded operations or acquisition activities. The combination of meaningfully reduced revenue and persistent operating losses raises questions about the company's near-term financial trajectory and ability to achieve profitability.

Comparing 2026-03-23 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

TLPH's financial position shows mixed signals with total assets growing to $29.7M from $18.2M and debt substantially reduced from $13.8M to $5.8M, but these improvements are overshadowed by revenue declining significantly to $2.2M from $8.0M. Cash decreased to $5.9M from $8.9M while operating losses remained substantial at $13.5M, though modestly improved from the prior year. The dramatic share count increase combined with revenue weakness suggests the company may be struggling operationally despite some balance sheet improvements.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+93.1%
$160K→$309K

Receivables surged 93.1% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Interest Expense
P&L
-88.4%
$1.2M→$134K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
-73.1%
$8.0M→$2.2M

Revenue declined 73.1% — significant demand weakness or market share loss warrants investigation.

Total Assets
Balance Sheet
+63%
$18.2M→$29.7M

Asset base grew 63% — expansion through organic growth, acquisitions, or capital deployment.

Total Debt
Balance Sheet
-58.2%
$13.8M→$5.8M

Debt reduced 58.2% — deleveraging strengthens balance sheet and reduces financial risk.

Current Liabilities
Balance Sheet
+43.9%
$2.6M→$3.8M

Current liabilities surged 43.9% — significant near-term obligations; verify ability to meet short-term debt.

Cash & Equivalents
Balance Sheet
-33.5%
$8.9M→$5.9M

Cash declined 33.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+23.9%
$10.2M→$12.7M

Liabilities increased 23.9% — monitor debt-to-equity ratio and interest coverage.

SG&A Expense
P&L
-12.4%
$8.5M→$7.5M

SG&A reduced 12.4% — improved cost efficiency or headcount reduction improving operating margins.

Operating Income
P&L
+11.6%
-$15.3M→-$13.5M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-31
ADDED
As of March 18, 2026, the number of outstanding shares of the registrant s common stock was 50,049,824 .
Fedsyra is a trademark, and Niyad and Zalviso are registered trademarks, all owned by Talphera, Inc.
In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the filing date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
+7 more — sign up free →
REMOVED
As of March 17, 2025, the number of outstanding shares of the registrant s common stock was 17,098,345 .
Niyad and Fedsyra are trademarks, and Zalviso are registered trademarks, all owned by Talphera, Inc.
Our common stock may be delisted from The Nasdaq Global Market if we cannot regain compliance with Nasdaq s continued listing requirements, which could limit our ability to raise additional capital in the future, limit our investors ability to make transactions in our common stock and subject us to additional trading restrictions.
We may fail to realize the benefits expected from our acquisition of Lowell Therapeutics, Inc., or Lowell, which could adversely affect our stock price.
We may fail to properly conduct and/or successfully complete our clinical trial for our lead product candidate, Niyad .
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →